LAUDER RONALD S

SEC source: 0001628280-26-024699 · wk-form4_1775852168.xml · derivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 4,768,846 shares

Expires not disclosed

F1 · derivative.exercise_price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · kind: The Reporting Person transferred shares to RSL Shares Trust u/a/d March 2, 2026 ('RSL Shares Trust') for no consideration.

F3 · price: Not applicable.

F1 · derivative.exercise_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · derivative.expiration_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-22-000015 · wf-form4_164461173803729.xml · derivative · entry 4

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,768,846

Underlying: Class A Common Stock · 700,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · kind: The Reporting Person converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F4 · price: Not applicable.

F2 · derivative.exercise_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · derivative.expiration_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-22-000015 · wf-form4_164461173803729.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001001250-22-000015 · wf-form4_164461173803729.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F2 · price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000067 · edgar.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001001250-21-000067 · edgar.xml · derivative · entry 4

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,468,846

Underlying: Class A Common Stock · 1,700,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · kind: Ronald S. Lauder ("RSL") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F3 · price: Not applicable.

F2 · derivative.exercise_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · derivative.expiration_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000067 · edgar.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,700,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Ronald S. Lauder ("RSL") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F2 · price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 8

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,371

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F9 · price: Sales prices range from $292.94 to $293.58 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 7

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,273

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F8 · price: Sales prices range from $291.94 to $292.93 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 6

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,794

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F7 · price: Sales prices range from $290.94 to $291.93 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 5

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 283,799

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F6 · price: Sales prices range from $289.94 to $290.93 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 4

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,200

F4 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F5 · price: Sales prices range from $288.93 to $289.91 per share, inclusive.

SEC source: 0001001250-21-000037 · edgar.xml · derivative · entry 10

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,168,846

Underlying: Class A Common Stock · 406,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · kind: Ronald S. Lauder ("RSL") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F3 · price: Not applicable.

F2 · derivative.exercise_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · derivative.expiration_date: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 3

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,000

F3 · price: Not applicable.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 370,000

F3 · price: Not applicable.

SEC source: 0001001250-21-000037 · edgar.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 406,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Ronald S. Lauder ("RSL") converted shares of Class B Common Stock into an equal number of shares of Class A Common Stock.

F2 · price: There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001001250-21-000038 · edgar.xml · nonDerivative · entry 3

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F4 · price: Sales prices range from $291.51 to $292.42 per share, inclusive.

SEC source: 0001001250-21-000038 · edgar.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,874

F1 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F3 · price: Sales prices range from $290.49 to $291.48 per share, inclusive.

SEC source: 0001001250-21-000038 · edgar.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Chairman, Clinique Labs LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,001

F1 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F1 · price: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.

F2 · price: Sales prices range from $289.45 to $290.31 per share, inclusive.

SEC source: 0001104659-20-032083 · tm2012151-1_4.xml · derivative · entry 5

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,574,846

Underlying: Class A Common Stock · 7,574,846 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: There is no exercise or conversion price for Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F1 · kind: The Reporting Person converted shares of Class B Common Stock to Class A Common Stock in settlement of an amended prepaid variable forward sale contract (the "Amended Contract").

F2 · price: There is no exercise or conversion price for Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · derivative.exercise_date: There is no exercise or conversion price for Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

F2 · derivative.expiration_date: There is no exercise or conversion price for Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001104659-20-032083 · tm2012151-1_4.xml · derivative · entry 4

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,828,685 shares

Expires 2020-03-11

F4 · derivative.exercise_price: On March 11, 2019, the Reporting Person entered into the Amended Contract with an unaffiliated third-party buyer with a maturity date of March 11, 2020. The contract obligated the Reporting Person to deliver to the buyer up to 2,000,000 shares of Class A Common Stock (or, at the Reporting Person's election, an equivalent amount of cash based on the market price of Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F5 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the Reporting Person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The Reporting Person has pledged 2,000,000 shares of Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the Reporting Person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F6 · derivative.exercise_price: Under the Amended Contract, the number of shares of Class A Common Stock delivered to the buyer at settlement on March 11, 2020 was based on the following formula, which referenced a settlement price determined by the arithmetic mean of the closing prices of Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price were less than $159.50, the Reporting Person would deliver 2,000,000 shares; (B) if the Settlement Price were less than $175.25, but equal to or greater than $159.50, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 divided by (ii) the Settlement Price;

F7 · derivative.exercise_price: and (C) if the Settlement Price were equal to or greater than $175.25, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 and $159.50 divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the Class A Common Stock. The Settlement Price was determined to be $183.8720 so pursuant to the formula, the Reporting Person delivered 1,828,685 shares of Class A Common Stock to buyer in settlement of the Amended Contract.

F4 · kind: On March 11, 2019, the Reporting Person entered into the Amended Contract with an unaffiliated third-party buyer with a maturity date of March 11, 2020. The contract obligated the Reporting Person to deliver to the buyer up to 2,000,000 shares of Class A Common Stock (or, at the Reporting Person's election, an equivalent amount of cash based on the market price of Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F5 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the Reporting Person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The Reporting Person has pledged 2,000,000 shares of Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the Reporting Person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F6 · kind: Under the Amended Contract, the number of shares of Class A Common Stock delivered to the buyer at settlement on March 11, 2020 was based on the following formula, which referenced a settlement price determined by the arithmetic mean of the closing prices of Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price were less than $159.50, the Reporting Person would deliver 2,000,000 shares; (B) if the Settlement Price were less than $175.25, but equal to or greater than $159.50, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 divided by (ii) the Settlement Price;

F7 · kind: and (C) if the Settlement Price were equal to or greater than $175.25, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 and $159.50 divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the Class A Common Stock. The Settlement Price was determined to be $183.8720 so pursuant to the formula, the Reporting Person delivered 1,828,685 shares of Class A Common Stock to buyer in settlement of the Amended Contract.

F4 · price: On March 11, 2019, the Reporting Person entered into the Amended Contract with an unaffiliated third-party buyer with a maturity date of March 11, 2020. The contract obligated the Reporting Person to deliver to the buyer up to 2,000,000 shares of Class A Common Stock (or, at the Reporting Person's election, an equivalent amount of cash based on the market price of Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F5 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the Reporting Person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The Reporting Person has pledged 2,000,000 shares of Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the Reporting Person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F6 · price: Under the Amended Contract, the number of shares of Class A Common Stock delivered to the buyer at settlement on March 11, 2020 was based on the following formula, which referenced a settlement price determined by the arithmetic mean of the closing prices of Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price were less than $159.50, the Reporting Person would deliver 2,000,000 shares; (B) if the Settlement Price were less than $175.25, but equal to or greater than $159.50, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 divided by (ii) the Settlement Price;

F7 · price: and (C) if the Settlement Price were equal to or greater than $175.25, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 and $159.50 divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the Class A Common Stock. The Settlement Price was determined to be $183.8720 so pursuant to the formula, the Reporting Person delivered 1,828,685 shares of Class A Common Stock to buyer in settlement of the Amended Contract.

SEC source: 0001104659-20-032083 · tm2012151-1_4.xml · nonDerivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F4 · kind: On March 11, 2019, the Reporting Person entered into the Amended Contract with an unaffiliated third-party buyer with a maturity date of March 11, 2020. The contract obligated the Reporting Person to deliver to the buyer up to 2,000,000 shares of Class A Common Stock (or, at the Reporting Person's election, an equivalent amount of cash based on the market price of Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F5 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the Reporting Person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The Reporting Person has pledged 2,000,000 shares of Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the Reporting Person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F6 · kind: Under the Amended Contract, the number of shares of Class A Common Stock delivered to the buyer at settlement on March 11, 2020 was based on the following formula, which referenced a settlement price determined by the arithmetic mean of the closing prices of Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price were less than $159.50, the Reporting Person would deliver 2,000,000 shares; (B) if the Settlement Price were less than $175.25, but equal to or greater than $159.50, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 divided by (ii) the Settlement Price;

F7 · kind: and (C) if the Settlement Price were equal to or greater than $175.25, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 and $159.50 divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the Class A Common Stock. The Settlement Price was determined to be $183.8720 so pursuant to the formula, the Reporting Person delivered 1,828,685 shares of Class A Common Stock to buyer in settlement of the Amended Contract.

F4 · price: On March 11, 2019, the Reporting Person entered into the Amended Contract with an unaffiliated third-party buyer with a maturity date of March 11, 2020. The contract obligated the Reporting Person to deliver to the buyer up to 2,000,000 shares of Class A Common Stock (or, at the Reporting Person's election, an equivalent amount of cash based on the market price of Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F5 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the Reporting Person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The Reporting Person has pledged 2,000,000 shares of Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the Reporting Person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F6 · price: Under the Amended Contract, the number of shares of Class A Common Stock delivered to the buyer at settlement on March 11, 2020 was based on the following formula, which referenced a settlement price determined by the arithmetic mean of the closing prices of Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price were less than $159.50, the Reporting Person would deliver 2,000,000 shares; (B) if the Settlement Price were less than $175.25, but equal to or greater than $159.50, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 divided by (ii) the Settlement Price;

F7 · price: and (C) if the Settlement Price were equal to or greater than $175.25, the Reporting Person would deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 and $159.50 divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the Class A Common Stock. The Settlement Price was determined to be $183.8720 so pursuant to the formula, the Reporting Person delivered 1,828,685 shares of Class A Common Stock to buyer in settlement of the Amended Contract.

SEC source: 0001104659-20-032083 · tm2012151-1_4.xml · nonDerivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,828,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The Reporting Person converted shares of Class B Common Stock to Class A Common Stock in settlement of an amended prepaid variable forward sale contract (the "Amended Contract").

F2 · price: There is no exercise or conversion price for Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

SEC source: 0001144204-19-013294 · tv515936_4.xml · derivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2020-03-11

F1 · derivative.exercise_price: On September 10, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 11, 2019, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 21, 2019 to March 11, 2020. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · derivative.exercise_price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price is less than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $175.25 (amended from $150.00 under the Prior Contract), but equal to or greater than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $175.25 (amended from $150.00 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 (amended from $150.00 under the Prior Contract) and $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On September 10, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 11, 2019, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 21, 2019 to March 11, 2020. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · kind: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price is less than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $175.25 (amended from $150.00 under the Prior Contract), but equal to or greater than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · kind: and (C) if the Settlement Price is equal to or greater than $175.25 (amended from $150.00 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 (amended from $150.00 under the Prior Contract) and $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On September 10, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 11, 2019, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 21, 2019 to March 11, 2020. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price is less than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $175.25 (amended from $150.00 under the Prior Contract), but equal to or greater than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · price: and (C) if the Settlement Price is equal to or greater than $175.25 (amended from $150.00 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 (amended from $150.00 under the Prior Contract) and $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001144204-19-013294 · tv515936_4.xml · derivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2019-05-21

F1 · derivative.exercise_price: On September 10, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 11, 2019, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 21, 2019 to March 11, 2020. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · derivative.exercise_price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price is less than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $175.25 (amended from $150.00 under the Prior Contract), but equal to or greater than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $175.25 (amended from $150.00 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 (amended from $150.00 under the Prior Contract) and $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On September 10, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 11, 2019, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 21, 2019 to March 11, 2020. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · kind: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price is less than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $175.25 (amended from $150.00 under the Prior Contract), but equal to or greater than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · kind: and (C) if the Settlement Price is equal to or greater than $175.25 (amended from $150.00 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 (amended from $150.00 under the Prior Contract) and $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On September 10, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 11, 2019, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 21, 2019 to March 11, 2020. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"): (A) if the Settlement Price is less than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $175.25 (amended from $150.00 under the Prior Contract), but equal to or greater than $159.50 (amended from $138.75 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · price: and (C) if the Settlement Price is equal to or greater than $175.25 (amended from $150.00 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $175.25 (amended from $150.00 under the Prior Contract) and $159.50 (amended from $138.75 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001144204-18-048941 · tv502660_4.xml · derivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2019-05-21

F1 · derivative.exercise_price: On February 6, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On September 10, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from November 20, 2018 to May 21, 2019. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · derivative.exercise_price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F4 · derivative.exercise_price: (A) if the Settlement Price is less than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $150.00 (amended from $151.8845 under the Prior Contract), but equal to or greater than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) the Settlement Price;

F5 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $150.00 (amended from $151.8845 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $150.00 (amended from $151.8845 under the Prior Contract) and $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On February 6, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On September 10, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from November 20, 2018 to May 21, 2019. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · kind: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F4 · kind: (A) if the Settlement Price is less than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $150.00 (amended from $151.8845 under the Prior Contract), but equal to or greater than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) the Settlement Price;

F5 · kind: and (C) if the Settlement Price is equal to or greater than $150.00 (amended from $151.8845 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $150.00 (amended from $151.8845 under the Prior Contract) and $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On February 6, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On September 10, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from November 20, 2018 to May 21, 2019. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F4 · price: (A) if the Settlement Price is less than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $150.00 (amended from $151.8845 under the Prior Contract), but equal to or greater than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) the Settlement Price;

F5 · price: and (C) if the Settlement Price is equal to or greater than $150.00 (amended from $151.8845 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $150.00 (amended from $151.8845 under the Prior Contract) and $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001144204-18-048941 · tv502660_4.xml · derivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2018-11-20

F1 · derivative.exercise_price: On February 6, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On September 10, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from November 20, 2018 to May 21, 2019. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · derivative.exercise_price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F4 · derivative.exercise_price: (A) if the Settlement Price is less than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $150.00 (amended from $151.8845 under the Prior Contract), but equal to or greater than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) the Settlement Price;

F5 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $150.00 (amended from $151.8845 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $150.00 (amended from $151.8845 under the Prior Contract) and $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On February 6, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On September 10, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from November 20, 2018 to May 21, 2019. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · kind: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F4 · kind: (A) if the Settlement Price is less than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $150.00 (amended from $151.8845 under the Prior Contract), but equal to or greater than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) the Settlement Price;

F5 · kind: and (C) if the Settlement Price is equal to or greater than $150.00 (amended from $151.8845 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $150.00 (amended from $151.8845 under the Prior Contract) and $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On February 6, 2018, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On September 10, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from November 20, 2018 to May 21, 2019. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge but the reporting person is required to make a cash payment upon the occurrence of certain dividends that may be declared prior to the maturity date.

F3 · price: Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F4 · price: (A) if the Settlement Price is less than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $150.00 (amended from $151.8845 under the Prior Contract), but equal to or greater than $138.75 (amended from $135.793 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) the Settlement Price;

F5 · price: and (C) if the Settlement Price is equal to or greater than $150.00 (amended from $151.8845 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $150.00 (amended from $151.8845 under the Prior Contract) and $138.75 (amended from $135.793 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001144204-18-006660 · tv485281_4.xml · derivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2018-11-20

F1 · derivative.exercise_price: On March 2, 2017, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On February 6, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from June 4, 2018 to November 20, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · derivative.exercise_price: (A) if the Settlement Price is less than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $151.8845 (amended from $93.4573 under the Prior Contract), but equal to or greater than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $151.8845 (amended from $93.4573 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $151.8845 (amended from $93.4573 under the Prior Contract) and $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On March 2, 2017, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On February 6, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from June 4, 2018 to November 20, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · kind: (A) if the Settlement Price is less than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $151.8845 (amended from $93.4573 under the Prior Contract), but equal to or greater than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · kind: and (C) if the Settlement Price is equal to or greater than $151.8845 (amended from $93.4573 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $151.8845 (amended from $93.4573 under the Prior Contract) and $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On March 2, 2017, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On February 6, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from June 4, 2018 to November 20, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · price: (A) if the Settlement Price is less than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $151.8845 (amended from $93.4573 under the Prior Contract), but equal to or greater than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · price: and (C) if the Settlement Price is equal to or greater than $151.8845 (amended from $93.4573 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $151.8845 (amended from $93.4573 under the Prior Contract) and $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001144204-18-006660 · tv485281_4.xml · derivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2018-06-04

F1 · derivative.exercise_price: On March 2, 2017, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On February 6, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from June 4, 2018 to November 20, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · derivative.exercise_price: (A) if the Settlement Price is less than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $151.8845 (amended from $93.4573 under the Prior Contract), but equal to or greater than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $151.8845 (amended from $93.4573 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $151.8845 (amended from $93.4573 under the Prior Contract) and $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On March 2, 2017, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On February 6, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from June 4, 2018 to November 20, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · kind: (A) if the Settlement Price is less than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $151.8845 (amended from $93.4573 under the Prior Contract), but equal to or greater than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · kind: and (C) if the Settlement Price is equal to or greater than $151.8845 (amended from $93.4573 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $151.8845 (amended from $93.4573 under the Prior Contract) and $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On March 2, 2017, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On February 6, 2018, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from June 4, 2018 to November 20, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · price: (A) if the Settlement Price is less than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $151.8845 (amended from $93.4573 under the Prior Contract), but equal to or greater than $135.793 (amended from $83.2953 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · price: and (C) if the Settlement Price is equal to or greater than $151.8845 (amended from $93.4573 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $151.8845 (amended from $93.4573 under the Prior Contract) and $135.793 (amended from $83.2953 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001209191-17-017654 · doc4.xml · derivative · entry 2

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000,000

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2018-06-04

F1 · derivative.exercise_price: On May 14, 2015, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 2, 2017, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 15, 2017 to June 4, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · derivative.exercise_price: (A) if the Settlement Price is less than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $93.4573 (amended from $104.5750 under the Prior Contract), but equal to or greater than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $93.4573 (amended from $104.5750 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $93.4573 (amended from $104.5750 under the Prior Contract) and $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On May 14, 2015, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 2, 2017, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 15, 2017 to June 4, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · kind: (A) if the Settlement Price is less than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $93.4573 (amended from $104.5750 under the Prior Contract), but equal to or greater than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · kind: and (C) if the Settlement Price is equal to or greater than $93.4573 (amended from $104.5750 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $93.4573 (amended from $104.5750 under the Prior Contract) and $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On May 14, 2015, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 2, 2017, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 15, 2017 to June 4, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · price: (A) if the Settlement Price is less than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $93.4573 (amended from $104.5750 under the Prior Contract), but equal to or greater than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · price: and (C) if the Settlement Price is equal to or greater than $93.4573 (amended from $104.5750 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $93.4573 (amended from $104.5750 under the Prior Contract) and $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

SEC source: 0001209191-17-017654 · doc4.xml · derivative · entry 1

LAUDER RONALD S · CIK 0000942617 · Director · Chairman, Clinique Labs, LLC · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,000,000 shares

Expires 2017-05-15

F1 · derivative.exercise_price: On May 14, 2015, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 2, 2017, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 15, 2017 to June 4, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · derivative.exercise_price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · derivative.exercise_price: (A) if the Settlement Price is less than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $93.4573 (amended from $104.5750 under the Prior Contract), but equal to or greater than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · derivative.exercise_price: and (C) if the Settlement Price is equal to or greater than $93.4573 (amended from $104.5750 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $93.4573 (amended from $104.5750 under the Prior Contract) and $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · kind: On May 14, 2015, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 2, 2017, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 15, 2017 to June 4, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · kind: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · kind: (A) if the Settlement Price is less than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $93.4573 (amended from $104.5750 under the Prior Contract), but equal to or greater than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · kind: and (C) if the Settlement Price is equal to or greater than $93.4573 (amended from $104.5750 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $93.4573 (amended from $104.5750 under the Prior Contract) and $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.

F1 · price: On May 14, 2015, the reporting person entered into an amended prepaid variable forward sale contract (the "Prior Contract") with an unaffiliated third party buyer. On March 2, 2017, the reporting person amended the Prior Contract (the "Amended Contract") which extended the maturity date on the outstanding prepaid variable forward contract from May 15, 2017 to June 4, 2018. The contract obligates the reporting person to deliver to the buyer up to 2,000,000 shares of EL Class A Common Stock (or, at the reporting person's election, an equivalent amount of cash based on the market price of EL Class A Common Stock at the time) following the maturity date of the contract subject to acceleration.

F2 · price: In exchange for assuming this obligation under the original prepaid variable forward sale contract in June 2011, the reporting person received a cash payment at that time. No payments were made by either party in connection with the Amended Contract. The reporting person has pledged 2,000,000 shares of EL Class B Common Stock (the "Pledged Shares") to secure his obligations under the Amended Contract, but retained voting and certain dividend rights in the Pledged Shares during the term of the pledge. Under the Amended Contract, the number of shares of EL Class A Common Stock to be delivered to the buyer at settlement will be based on the following formula, which references a settlement price that will be determined by the arithmetic mean of the closing prices of EL Class A Common Stock on each of the five trading days up to, and including, the maturity date (the "Settlement Price"):

F3 · price: (A) if the Settlement Price is less than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver 2,000,000 shares; (B) if the Settlement Price is less than $93.4573 (amended from $104.5750 under the Prior Contract), but equal to or greater than $83.2953 (amended from $75.6500 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio of (i) $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) the Settlement Price;

F4 · price: and (C) if the Settlement Price is equal to or greater than $93.4573 (amended from $104.5750 under the Prior Contract), the reporting person will deliver a number of shares equal to 2,000,000 multiplied by a ratio equal to one minus (i) the difference between $93.4573 (amended from $104.5750 under the Prior Contract) and $83.2953 (amended from $75.6500 under the Prior Contract) divided by (ii) Settlement Price, subject in each case to adjustment upon the occurrence of certain corporate events applicable to the EL Class A Common Stock. The number of shares of EL Class A Common Stock to be delivered and the number of Pledged Shares are also subject to adjustment in such event.